PWM
HRTX icon

Palumbo Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Palumbo Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-412,496
Closed -$330K – 240
2026
Q1 		$330K Buy
412,496
+153,083
+59% +$177K 0.08% 160
2025
Q4 		$337K Buy
259,413
+42,907
+20% +$53K 0.08% 159
2025
Q3 		$273K Buy
216,506
+84,073
+63% +$133K 0.09% 142
2025
Q2 		$274K Buy
132,433
+8,330
+7% +$17K 0.08% 149
2025
Q1 		$273K Buy
+124,103
New +$241K 0.09% 141

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Palumbo Wealth Management's HRTX Position: Q2 2026 in Review

Palumbo Wealth Management sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 412,496 shares — an estimated $330K sold.

Palumbo Wealth Management first reported a position in HRTX in Q1 2025 and held it in 5 quarters. The position peaked at $337K in Q4 2025. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Palumbo Wealth Management reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Palumbo Wealth Management sold 412,496 Heron Therapeutics shares in Q2 2026, an estimated $330K.
  • Palumbo Wealth Management first reported a position in Heron Therapeutics in Q1 2025 and held it in 5 quarters.
  • Palumbo Wealth Management's Heron Therapeutics position peaked at $337K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.